The current health and economic crisis will impact corporate VC’s investment strategies over the coming months.
For healthcare and life science CVCs, the accelerated development, regulatory approval, and adoption of new screening tools, diagnostics, and treatments will create a wealth of opportunities.
During the session, we will hear from experienced investors in this field about their perspectives on the current market dynamics and how these may eventually shape their own investment decisions.
Marc Filerman, CEO, German Accelertor Life Sciences
Rohan Ganesh, Principal, Venture Capital, Verily Life Sciences
Joey Mason, Head of Life Sciences Fund, M Ventures